Research and development based on 3 categories: cancer, rheumatism and dialysis
First written in FY2018. 4 of 5 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「The basic policy for research and development is to internally develop high-value-added generic drugs based on 3 patient categories: cancer, rheumatism, and dialysis.」
The company has reconfirmed its policy of internally developing high-value-added generic drugs based on the 3 categories of cancer, rheumatism, and dialysis. - FY2025RestatedAnnual report
「The basic policy for research and development is to internally develop high-value-added generic drugs based on 3 patient categories: cancer, rheumatism, and dialysis.」
The company has reconfirmed its research and development policy for high-value-added generic drugs based on the 3 categories of cancer, rheumatism, and dialysis. - FY2021RestatedAnnual report
「Our basic policy is to research and develop generic drugs based on 3 patient categories—cancer, rheumatism, and dialysis—and provide high-value-added pharmaceuticals.」
The company has reconfirmed its policy of focusing on priority patient categories in research and development and providing high-value-added products. - FY2019RestatedAnnual report
「Our basic policy is to research and develop generic drugs based on 3 patient categories—cancer, rheumatism, and dialysis—and provide high-value-added pharmaceuticals.」
The company continues to identify its priority categories for research and development. - FY2018First statedAnnual report
「Our basic policy is to research and develop generic drugs based on 3 patient categories—cancer, rheumatism, and dialysis—and provide high-value-added pharmaceuticals.」
A basic policy identifying the priority patient categories for research and development.